newsfilter
← Latest News
Business Wire·

Natera Announces IVDR Certification for Signatera™ Across Multiple Cancers

Signatera is the first personalized molecular residual disease (MRD) test for solid tumors to receive IVDR certification in the EU Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine,